API | volanesorsen sodium

volanesorsen sodium Report issue

Biologics Nucleic acid Experimental

AACT ChEMBL PubChem

Active Ingredient History

NOW

Volanesorsen, sold under the brand name Waylivra, is a triglyceride-reducing drug. It is a second-generation 2'-O-methoxyethyl (2'-MOE) chimeric antisense therapeutic oligonucleotide (ASO) that targets the messenger RNA for apolipoprotein C3 (apo-CIII). ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules:

volanesorsen sodium

volanesorsen

More Chemistry

Pharmacology

Mechanisms of Action:
- Apolipoprotein C-III (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

free acid | isis 304801 | isis-304801 | volanesorsen | volanesorsen sodium

Organizations (4)

Research & Development (4)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (7)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (7)

Cardiovascular Abnormalities (Phase 1)

Chylomicrons (Phase 3)

Hyperlipoproteinemia Type I (Phase 3)

Hypertriglyceridemia (Phase 3)

Lipodystrophy (Phase 2)

Lipodystrophy, Familial Partial (Phase 2/Phase 3)

Lipoproteins (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 7
# of Trial Organizations: 4

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue